Amide Proton Transfer-weighted MRI combined with serum prostate-specific antigen levels for differentiating malignant prostate lesions from benign prostate lesions: a retrospective cohort study

Table 4 Ability of the quantitative parameters in differentiating malignant from benign prostate diseases

	Malignant (n = 52)	Benign (n = 27)	Z/t	P value
APTmean (%)	2.740 ± 1.106	1.859 ± 1.200	-3.263	0.002
APTmax (%)	6.698 ± 1.837	4.530 ± 1.894	-4.924	< 0.001
APTmin (%)	-1.788 ± 2.557	-1.259 ± 1.815	0.965	0.342
ADCmean (10^–3 mm²/s)	0.845 (0.300–2.030)	1.190 (0.620–1.680)	-4.259	< 0.001
ADCmax (10^–3 mm²/s)	1.450 ± 0.445	1.738 ± 0.391	2.835	0.006
ADCmin (10^–3 mm²/s)	0.464 ± 0.356	0.646 ± 0.271	2.330	0.022
tPSA (ng/mL)	33.604 (0.600–8169.000)	6.053 (0.840–131.760)	-3.321	0.001
FPSA (ng/mL)	3.959 (0.020–483.000)	1.230 (0.210–7.240)	-2.506	0.012
FPSA/tPSA	16.159 ± 15.300	23.336 ± 12.954	2.074	0.043
PSAD (ng/mL/cm³)	10.585 (0.010–688.540)	1.980 (0.030–38.650)	-2.884	0.004

APT amide proton transfer, ADC apparent diffusion coefficient, tPSA total prostate-specific antigen, FPSA free prostate-specific antigen, PSAD prostate-specific antigen density

ISSN: 1470-7330